A Mother’s Last Hope to Save Her Daughter’s Life
source: pixabay.com

A Mother’s Last Hope to Save Her Daughter’s Life

  CBC News Canada carried the story of a 23-year-old patient, Morgan Buyaki of Saskatchewan, Canada, who was diagnosed eighteen months ago with eosinophilic granulomatosis with polyangiitis (EGPA). Morgan’s mother…

Continue Reading A Mother’s Last Hope to Save Her Daughter’s Life

Don’t Miss National Eosinophil Awareness Week!

It's time to raise awareness for and celebrate the patient population that lives with eosinophilic disorders. From May 15th until the 21st, the American Partnership for Eosinophilic Disorders (APFED) is…

Continue Reading Don’t Miss National Eosinophil Awareness Week!

Study Determined Symptom Prevalence Amongst Subtypes of AAVs

A recent study has examined the characteristics and the clinical outcomes for individuals with severe anti-neutrophil cytoplasmic antibody-associated vasculitides (AAVs). AAVs are a very rare group of systemic autoimmune conditions.…

Continue Reading Study Determined Symptom Prevalence Amongst Subtypes of AAVs

Nucala is Now Approved For 4 Rare Eosinophil-Based Diseases in Europe

GlaxoSmithKline has recently announced their new approval of Nucala by the European Commission. This therapy has been approved for three new diseases, all of which are driven by eosinophils. Nucala is…

Continue Reading Nucala is Now Approved For 4 Rare Eosinophil-Based Diseases in Europe

New Therapy for Eosinophilic Granulomatosis with Polyangiitis May be Coming to Europe

The EMA has recently published their recommendation for extending the indication of a treatment called Nucala to include patients diagnosed with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Specifically,…

Continue Reading New Therapy for Eosinophilic Granulomatosis with Polyangiitis May be Coming to Europe
Nucala Recommended for Three New Indications
stevepb / Pixabay

Nucala Recommended for Three New Indications

Nucala has already been approved in Europe as an add-on treatment for patients with extreme eosinophilic asthma. Now, the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended…

Continue Reading Nucala Recommended for Three New Indications
A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA
qimono / Pixabay

A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA

Corticosteroids are used to treat a wide variety of inflammatory conditions, with asthma and arthritis acting as examples. However, these drugs can result in a variety of side effects, such…

Continue Reading A Combination of Nucala and Corticosteroids Was Shown to Increase Remission in EGPA
Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study
source: pixabay.com

Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Nucala’s Effectiveness in EGPA Confirmed in Real-World Study